- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00721435
Combined Digital X-ray and Ultrasound Technique for Improved Detection and Characterization of Breast Lesions
January 22, 2017 updated by: Paul L. Carson Ph.D, University of Michigan
The study will evaluate and refine a breast screening and diagnosis device.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The device produces 3-D mammograms and ultrasound pictures of the breast at the same time and in the same position.
This should help make sure that any area on a mammogram can be easily found in the ultrasound when using the new device.
The 3-D mammograms should provide better visualization of the suspected lesion and improve diagnostic accuracy.
Study Type
Interventional
Enrollment (Actual)
183
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
Ann Arbor, Michigan, United States, 48109-0554
- University of Michigan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- To participate in this research study you must be a female over the age of 25
- Have had a normal mammogram or are scheduled for a breast biopsy
- Have cysts or have been recommended to have a 6 month follow up mammogram after your biopsy.
Exclusion Criteria:
- Male
- Under the age of 25
- Documented breast cancer
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 3D Tomosynthesis & 3D Ultrasound for breast masses
Evaluate breast screening diagnostic device, 3D tomosynthesis.
Assess utility of adding 3D ultrasound.
|
3D tomosynthesis & ultrasound imaging for scanning masses or healthy breast tissue
|
Experimental: 3D Tomosynthesis/ 3D Ultrasound for healthy subjects
Evaluate breast screening diagnostic device, 3D tomosynthesis.
Assess utility of adding 3D ultrasound.
|
3D tomosynthesis & ultrasound imaging for scanning masses or healthy breast tissue
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To have a device that produces 3D/ultrasound imaging of the breast at the same time and in the same position.
Time Frame: To be determined later.
|
To be determined later.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Paul L Carson, PHD, University of Michigan
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2002
Primary Completion (Actual)
December 1, 2014
Study Completion (Actual)
October 1, 2016
Study Registration Dates
First Submitted
July 22, 2008
First Submitted That Met QC Criteria
July 22, 2008
First Posted (Estimate)
July 24, 2008
Study Record Updates
Last Update Posted (Estimate)
January 24, 2017
Last Update Submitted That Met QC Criteria
January 22, 2017
Last Verified
January 1, 2017
More Information
Terms related to this study
Other Study ID Numbers
- HUM00045519 (2002-0584)
- R01CA091713 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on 3D Tomosynthesis and ultrasound imaging
-
University of GenovaUniversity of SydneyUnknown
-
Delphinus Medical Technologies, Inc.Completed
-
GE HealthcareTerminatedBreast Cancer | Tumors, BreastFrance, United States
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Pieter MuntendamIcahn School of Medicine at Mount Sinai; AstraZenecaEnrolling by invitationHeart Diseases | Stroke | Plaque, Atherosclerotic | Cardiovascular Risk Factor | Atherosclerotic DiseaseUnited States
-
University of MichiganNational Institutes of Health (NIH)Withdrawn
-
Mayo ClinicTerminated
-
GE HealthcareCompletedBreast Cancer | Cancer Screening | Tumors, BreastUnited States
-
Sunnybrook Health Sciences CentreNot yet recruiting